KYVERNA THERAPEUTICS, INC. COMMON STOCK
NASDAQ: KYTX (Kyverna Therapeutics, Inc.)
Kemas kini terakhir: 2 hari lalu, 8:59PM7.30
-0.19 (-2.54%)
| Penutupan Terdahulu | 7.49 |
| Buka | 7.52 |
| Jumlah Dagangan | 523,948 |
| Purata Dagangan (3B) | 1,046,968 |
| Modal Pasaran | 443,805,056 |
| Harga / Buku (P/B) | 2.20 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Aug 2026 |
| EPS Cair (TTM) | -3.24 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.10% |
| Nisbah Semasa (MRQ) | 7.44 |
| Aliran Tunai Operasi (OCF TTM) | -133.64 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -80.19 M |
| Pulangan Atas Aset (ROA TTM) | -31.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -49.72% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Kyverna Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -3.5 |
| Osilator Teknikal | -0.5 |
| Purata | -2.00 |
|
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 12.04% |
| % Dimiliki oleh Institusi | 68.57% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Vida Ventures Advisors, Llc | 30 Sep 2025 | 4,523,924 |
| Gilead Sciences, Inc. | 31 Mar 2026 | 4,126,119 |
| Deerfield Management Company, L.P. | 31 Mar 2026 | 2,000,000 |
| Insight Holdings Group, Llc | 31 Mar 2026 | 989,054 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |